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Abstract
Background: The World Health Organisation (WHO) recommends parasitological diagnosis of malaria before
treatment, but use of malaria rapid diagnostic tests (mRDTs) by community health workers (CHWs) has not been
fully tested within health services in south and central Asia. mRDTs could allow CHWs to diagnose malaria
accurately, improving treatment of febrile illness.
Methods: A cluster randomised trial in community health services was undertaken in Afghanistan. The primary
outcome was the proportion of suspected malaria cases correctly treated for polymerase chain reaction (PCR)-
confirmed malaria and PCR negative cases receiving no antimalarial drugs measured at the level of the patient.
CHWs from 22 clusters (clinics) received standard training on clinical diagnosis and treatment of malaria; 11 clusters
randomised to the intervention arm received additional training and were provided with mRDTs. CHWs enrolled
cases of suspected malaria, and the mRDT results and treatments were compared to blind-read PCR diagnosis.
Results: In total, 256 CHWs enrolled 2400 patients with 2154 (89.8%) evaluated. In the intervention arm, 75.3% (828/
1099) were treated appropriately vs. 17.5% (185/1055) in the control arm (cluster adjusted risk ratio: 3.72, 95%
confidence interval 2.40–5.77; p < 0.001). In the control arm, 85.9% (164/191) with confirmed Plasmodium vivax received
chloroquine compared to 45.1% (70/155) in the intervention arm (p < 0.001). Overuse of chloroquine in the control arm
resulted in 87.6% (813/928) of those with no malaria (PCR negative) being treated vs. 10.0% (95/947) in the intervention
arm, p < 0.001. In the intervention arm, 71.4% (30/42) of patients with P. falciparum did not receive artemisinin-based
combination therapy, partly because operational sensitivity of the RDTs was low (53.2%, 38.1–67.9). There was high
concordance between recorded RDT result and CHW prescription decisions: 826/950 (87.0%) with a negative test were
not prescribed an antimalarial. Co-trimoxazole was prescribed to 62.7% of malaria negative patients in the intervention
arm and 15.0% in the control arm.
Conclusions: While introducing mRDT reduced overuse of antimalarials, this action came with risks that need to be
considered before use at scale: an appreciable proportion of malaria cases will be missed by those using current
mRDTs. Higher sensitivity tests could be used to detect all cases. Overtreatment with antimalarial drugs in the control
arm was replaced with increased antibiotic prescription in the intervention arm, resulting in a probable overuse of
antibiotics.
Trial registration: ClinicalTrials.gov, NCT01403350. Prospectively registered.
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Background
Acute febrile illness is one of the commonest presenta-
tions to clinics in Asia, with malaria being one of mul-
tiple possible causes. Malaria rapid diagnostic tests
(mRDTs) are increasingly used across health service set-
tings to improve diagnosis and treatment of febrile ill-
ness by detecting malaria [1]. The World Health
Organisation (WHO) recommends universal coverage
with diagnostic testing for malaria to ensure that pa-
tients are appropriately prescribed artemisinin combin-
ation therapy (ACT) and other antimalarial drugs [2]
and improving treatment of other causes of febrile ill-
ness. Wider use of mRDTs should also improve disease
surveillance, particularly in areas of low to moderate
transmission where malaria elimination is being
considered.
There is now reasonable evidence to support WHO
policy on the effect of using falciparum-specific RDTs in
highly endemic areas in Africa, where almost all malaria
is caused by Plasmodium falciparum [3–7]. As a result,
RDTs are now widely used in Africa, and their use is
growing [8]. There is much less evidence from Asia,
where more than one billion people live in malaria en-
demic areas [9] which are co-endemic for P. falciparum
and P. vivax and where the proportion of febrile patients
who have malaria is generally much lower than in Africa.
Afghanistan is typical of much of low-resource south
Asia, where P. vivax makes up around 85–95% of
malaria cases [10].
Community health workers (CHWs) are often the first
point of contact with healthcare services for those with
fever or a history of fever. In common with much of
south Asia, CHWs in Afghanistan have limited training
and do not have access to laboratory testing. Currently
malaria reported in this setting is diagnosed using clin-
ical signs and symptoms alone which are indistinguish-
able from many other causes of fever. This is termed
’suspected malaria’ in training curricula and treatment
guidelines and is often treated presumptively with
chloroquine (CQ) and/or sulphadoxine-pyrimethamine
(SP) since there is no way of distinguishing the species
of malaria necessary to guide treatment. This approach
leads to misdiagnosis and overtreatment of malaria,
sometimes resulting in 100% mistreatment and antimal-
arial wastage in areas of very low malaria endemicity
[11, 12]. In initial testing in health facilities where
healthcare workers have formal training, an earlier study
in this Afghan setting showed that diagnosis using
mRDTs led to improved prescribing of antimalarial
drugs at an individual level and an increase in prescrib-
ing of antibiotics [11].
We therefore conducted a two-arm, stratified cluster
randomised trial amongst communities within the for-
mal health service in two provinces of Afghanistan to
investigate the effect of training and the use of mRDTs
on accurate diagnosis and appropriate prescribing of
antimalarials and antibiotics by CHWs compared
to normal clinical diagnosis. A cluster randomised de-
sign was chosen because a patient randomised trial in
the setting of CHWs is unlikely to give accurate esti-
mates of effect. This happens because prescribers influ-
ence one another (a healthcare worker community
effect), and perceptions of interventions may influence
normal practice by the community (a patient commu-
nity effect) [13].
Methods
Study setting
Clinics were purposively selected if the location was
relatively secure, part of the formal public health system
and provided outpatient care for febrile illnesses, includ-
ing malaria [11]. Twenty-two clinics (clusters) were se-
lected. Twelve of these were in an area defined as being
of ’moderate transmission’ in the National Malaria Strat-
egy [10] in the eastern region of Afghanistan (malaria in-
cidence of 1–10 per 1000 per year). Ten clinics were in
an area defined as being of low transmission in northern
Afghanistan (<1 per 1000 per year) [10–12].
The Afghan public health system comprises Basic
Health Centres (BHC), Comprehensive Health Centres
(CHC) and District Hospitals. Our study clinics were all
BHCs or CHCs which provide outpatient services for
acute illnesses. Each health centre employs CHWs to
serve a population of 5000–10,000 people each. CHWs
perform a range of curative and preventative tasks in-
cluding treatment of acute illnesses, antenatal care,
vaccination (under the Extended Programme of Immun-
isation) and health education and awareness. They are
often the first point of contact with health services, espe-
cially in rural and poorer areas. CHWs are volunteers
who do not receive a wage (although they sometimes re-
ceive payments for services, such as completing national
surveys). Being a CHW is not a full-time task, and
CHWs are often teachers, farmers or religious leaders or
have other occupations. They receive a 6-week basic
training before being deployed, but also receive add-
itional training provided by the government or non-
governmental organisations (NGOs) in various guide-
lines and approaches to community health work. The
approaches they follow are based on Integrated Manage-
ment of Childhood Illness (IMCI) guidelines and defini-
tions, although it is unknown how well these guidelines
are applied in practice. CHWs are supervised by a com-
munity health manager who supplies basic items, includ-
ing essential medicines. CHWs keep records of
consultations and activities which are entered into the
national health information system. They operate, nor-
mally, as a married couple from a health post or house.
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BHCs and CHCs were used as the units of randomisa-
tion (cluster) in this study.
Sample size and randomisation
Introducing RDTs to community centres with associated
training is a major public health effort, so it would only
be justified with a substantial public health benefit.
Based on randomisation of 22 clusters, 2542 individuals
would be required to detect an absolute increase in the
primary outcome (appropriate treatment) from 10% in
the control arm (from previous observational data) to
50% in the intervention arm with 80% power at the 5%
significance level, assuming a between-cluster coefficient
of variation (κ) of 0.5. The sample size was weighted ac-
cording to the total number of consultations per cluster
to give an overall harmonic mean of 68 patients per
cluster.
Clinics were stratified by province and randomised
within strata through a process of restricted (con-
strained) randomisation, to ensure marginal balance
across strata and study arms on covariates expected to
be important correlates of the primary outcome [14].
Balance was achieved for the following: total sample size
per arm differing by no more than 50; harmonic mean
number of patients per cluster between 65 and 71; num-
ber of health posts (CHW houses) per arm differing by
no more than 10. These restriction criteria led to 1589
acceptable allocations, of which one was chosen at ran-
dom. Randomisation was conducted by one of the trial
statisticians (BC), who was not involved in the delivery
of the intervention or assessment or final analysis of the
study outcomes, using a program written in R statistical
software version 2.13.0.
Intervention and control arms
The two arms of the trial were (1) training on the na-
tional guidelines for community-based management of
malaria (control) and (2) the same training as the con-
trol plus additional training in the use of RDTs and
provision of RDTs for use in practice (intervention). A
description of the control and intervention arms is given
in Table 1.
The appropriate training for the study arm was con-
ducted at the clinics prior to data collection by national
trainers who were not part of the study team, and this
training was designed to be possible for a malaria con-
trol programme to provide routinely. Some training ses-
sions were observed by study staff (IM) to ensure that it
was done according to the training curriculum. All
CHWs associated with the study clinics were eligible for
the training.
The 1-day training curriculum for all CHWs in both
the control and intervention arms covered the basics of
malaria and transmission, diagnosis of suspected malaria
according to clinical signs and symptoms, national treat-
ment guidelines and the national strategy to control
malaria. In the control arm, CHWs had a stock of CQ
and SP for treatment of suspected malaria. In the inter-
vention arm, CHWs additionally received a practical
module on the use of mRDTs and provision of ACT
treatment (sulphadoxine/pyrimethamine and artesunate,
Table 1 Intervention description
Training/intervention description Control arm (no RDTs) Intervention arm (RDTs)
Basic CHW training 6-week basic training in preventative and curative services for
infectious diseases, nutrition and mother-and-child health.
Malaria and malaria treatment guidelines are included in the
curriculum. Includes record keeping for health service reporting
(Health Management Information System, HMIS)
√ √
Malaria training 1-day refresher workshop on control, treatment and surveillance
for malaria, including the guidelines for community-based
treatment of suspected malaria
√ √
mRDT training Half-day training on use of mRDTs, including symptoms, practical
and demonstrated use of mRDTs and treatment guidelines for
RDT-confirmed P. falciparum
X √
mRDTs Bivalent immunofluorescent antigen detection tests for diagnosis
of P. falciparum (histidine-rich protein 2, HRP2) and pan-specific
Plasmodium lactate dehydrogenase (pLDH). See text for
manufacturer details
X √
ACTs Sulphadoxine-pyrimethamine with artesunate according to
standard dosing table for adults and children in co-blister packs.
For treatment of RDT-confirmed P. falciparum
X √
SP and CQ For treatment of suspected malaria (SP and/or CQ) and treatment
of pan-specific positive and P. falciparum negative RDTs
√ √
Co-trimoxazole For treatment of pneumonia in children; included in the standard
package of drugs provided to CHWs
√ √
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SP/AS) for cases of mRDT positive P. falciparum and
CQ for mRDT positive pan-specific (assumed to be P.
vivax malaria). The module was based on WHO guide-
lines [2] and written by a National Malaria Programme
Task Force. CHWs were given a take-home reference
sheet with pictorial instructions on how to use the
mRDT and provide treatment (Additional file 1). After
the training, CHWs were provided with mRDTs, drugs
and other materials for using mRDTs and applying treat-
ment. The mRDTs were CareStart Malaria HRP2/pLDH
(Pf/pan) Combo Tests, approved by WHO-FIND [15, 16].
Supplies were replenished when needed.
Data collection and participant enrolment
Two weeks after training, all CHWs from both study arms
were recalled and trained in study data collection methods
if they gave consent to participate in the study. They were
instructed on use of a pre-tested semi-pictorial form for
recording data on each patient consultation (Additional
file 1). This included details of age and gender, symptoms
and their time of onset, diagnosis, treatment given and re-
ferral. The intervention arm form had space for recording
mRDT results (Additional file 1). Training was given on
blood safety, including information on standard precau-
tions and safe disposal of sharps and blood-contaminated
materials.
Patients of any age were enrolled by CHWs if they
gave informed consent and presented with symptoms
suspected to be due to malaria (fever or history of fever
and chills). Patients were excluded if they had sought
care for the episode of illness from any other source; if
the CHW referred the patient directly to the clinic for
any reason prior to diagnosis; or if they had any signs of
severe illness. Patients who were not enrolled received
care according to standard guidelines. Patients exited
the trial at the end of the consultation with the CHW.
No further formal follow-up was required by the proto-
col due to the operational difficulties of doing so in
Afghanistan.
Laboratory procedures
All patients had a blood-spot filter paper (Whatman
3MM chromatography paper) collected at enrolment by
the CHW; this was used to provide the gold standard
polymerase chain reaction (PCR) diagnosis used to de-
fine the outcomes. CHWs in Afghanistan do not take
and store malaria blood slides, so it was not possible to
collect them from patients in the trial. Filter-paper blood
samples were analysed using standard PCR methods out-
lined previously [11]. The PCR analysis was batched and
undertaken blind to study arm allocation at the National
Malaria Control Programme Laboratories in Kabul.
Outcome measures
The primary outcome was the proportion of patients ap-
propriately treated with antimalarial drugs by the
CHWs. This was a composite measure defined against
the malaria PCR result for each patient: falciparum or
mixed-species malaria treated with SP/AS, vivax malaria
treated with CQ (regardless of accompaniment with SP)
and PCR-confirmed negative cases receiving no antimal-
arial drug.
Secondary outcomes were as follows: antimalarial treat-
ment accuracy disaggregated by species (i.e. proportion of
falciparum cases receiving ACT, proportion of vivax mal-
aria cases receiving CQ); proportion of malaria (PCR)
negative cases receiving antimalarials and the proportion
receiving antibiotics; and prescription of antimalarials by
recorded RDT result. An additional analysis was under-
taken in those under 5 and those over 5 years of age. The
study also evaluated the accuracy of the mRDT against
PCR results and the concordance between the mRDT re-
sult given by the CHW and a second read by the trained
study registrar, during which we used a WHO-FIND and
nationally approved bivalent test [15, 16] capable of de-
tecting pan-specific Plasmodium lactase dehydrogenase
(pLDH) and P. falciparum-specific histidine-rich protein 2
(HRP2).
Statistical analysis
Data were double entered into an MS Access database
and analysed using STATA v12 (2011, StataCorp.,
College Station, TX, USA). The analysis was conducted
on an intention-to-treat basis, and the effect of the inter-
vention was analysed using methods suitable for cluster
randomised trials with fewer than 20 clusters per arm
[17]. The observed percentage treated appropriately was
calculated for each clinic (cluster), and the mean of the
cluster-level estimates was taken to give the prevalence
of the primary outcome in each arm. Due to the skew-
ness in the distribution of the cluster proportions, a log
transformation was applied, and the mean of the log
proportions was estimated in each arm and stratum.
Given the equal number of clusters allocated to the
study arms within each stratum, the risk ratio (RR) for
the intervention effect was computed from exponenti-
ation of the difference between the mean of the log pro-
portions in each arm. Corresponding 95% confidence
intervals (CIs) for the RRs were based on the loga-
rithm of the RR, and a stratified t test was used to test
the null hypothesis of no overall intervention effect.
The pooled variance of the log proportions within
each stratum-arm combination was estimated as the
residual mean square from a two-way analysis of vari-
ance (ANOVA) incorporating the stratum by study
arm interaction. An estimate of the between-cluster
variation, k, was calculated [17].
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The main analyses were adjusted for pre-defined po-
tential confounders, based on information from charac-
teristics of clusters, CHWs and patients and the way in
which they differed by trial arm at baseline. A range of
confounding factors were considered for inclusions in
the model, but were not independently associated with
the main outcome and so were not included in the final
analysis. These included patient-level factors (age, gen-
der, pregnancy, symptoms at presentation, days since on-
set of symptoms); CHW-level factors (gender, age,
socioeconomic group of the CHW, length of service,
training history) and cluster-level factors (clinic type
(CHC/BHC); malaria slide positivity rate).
Adjustment for covariates was made by fitting a logis-
tic regression model using data on individuals, and in-
cluding the covariates of interest and the intervention
effect. Expected numbers with appropriate treatment
were computed, in the absence of the intervention for
intervention clinics, and compared with the observed
values to provide ratio residuals for each clinic. Risk ra-
tios, 95% CIs and hypothesis testing were calculated
using the above methods, with the residuals replacing
cluster-specific proportions.
Ethics and trial registration
The trial protocol was reviewed and approved by the eth-
ics committee of the Institutional Review Board, Ministry
of Public Health, Afghanistan, the Ethics Committee of
the London School of Hygiene & Tropical Medicine and a
Data Safety Monitoring Board. The trial was prospectively
registered at ClinicalTrials.gov, NCT01403350.
Results
Patients were enrolled between October 2011 and May
2012, 22 clinics were randomised and of the 256 CHWs,
222 (86.7%) received training in the study data collection
methods, consented and enrolled patients. Those who
did not enrol patients were either not present for train-
ing or did not give consent to participate. The trial
ended when the sample size had been reached.
Enrolment characteristics
Table 2 shows the characteristics of the clinics, health
posts, CHWs and patients enrolled in the study, and
Fig. 1 shows the trial profile. Most key characteristics
differed minimally between the control and intervention
arms of the trial.
Data from 246/2400 patients (10.1%) were not evalu-
able either because of missing reference diagnoses (n =
38) or missing outcome data (diagnosis and/or treatment
not recorded on the case record form) (n = 209).
Primary outcome
The proportion of patients appropriately treated for mal-
aria was substantially higher in the intervention arm
(828/1099, 75.3%) than in the control arm (185/1055,
17.5%); after adjusting for study design the risk ratio was
3.72 (95% CI: 2.40–5.77, p < 0.001) (Table 3). The pro-
portion of health posts that provided accurate treatment
to fewer than 50% of all patients who presented was 94/
101 (93.1%) in the control arm and 20/111 (18.0%) in
the intervention arm (Fig. 2).
Secondary outcomes
Targeting of antimalarial drugs and use of the antibiotic
co-trimoxazole and antipyretics
A higher proportion of patients without malaria (defined
as having a negative PCR result for malaria) were treated
with antimalarial drugs in the control arm than in the
mRDT arm (Table 3) (87.6% vs. 10.0%, p < 0.001). This
major reduction in treating non-malaria patients with
antimalarials was the main reason for the improvement
in appropriate treatment.
Amongst the 42 cases of confirmed P. falciparum mal-
aria in the intervention arm, only 28.6% (n = 12) received
ACT. Of the 30 patients who did not receive ACT, 21
were missed by CHWs being guided by the mRDT result
(false negative results). Of the 9 who were correctly diag-
nosed as P. falciparum positive by the RDT, 3 received
CQ and 6 received no antimalarial drugs. ACTs were
not available to the control arm as per local policy for
treating unconfirmed malaria. However, in this arm, of
44 falciparum cases detected by PCR, 4 received no anti-
malarial drug, 34 received CQ monotherapy and 6 re-
ceived SP and CQ. The net effect of introducing mRDTs
was therefore a lower proportion of patients with falcip-
arum malaria being given an antimalarial.
For vivax in the control arm, most patients were
treated presumptively with CQ. A higher proportion of
patients with PCR-confirmed P. vivax received CQ (the
first-line treatment) in the control arm than in the
mRDT arm (85.9% (n = 168) vs. 45.1% (n = 70), p <
0.001).
Amongst those with no malaria (PCR negative), 67.2%
in the mRDT arm received the antibiotic co-trimoxazole,
supplied to CHWs to treat pneumonia, compared to
35.0% in the control arm (p = 0.012). Antipyretics were
prescribed to 846 (78.8%) in the control arm and 948
(84.8%) in the intervention arm (p < 0.001).
CHW prescription decisions by RDT result
Analysis of CHW response to the RDT result shows that
826/950 (87.0%) of those with a negative mRDT result
were not prescribed an antimalarial drug. In 117/149
(78.5%) of cases where a single line (pan line) (signifying
vivax malaria) was recorded, CQ was prescribed as per
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Table 2 Enrolment characteristics of clinics, CHWs and patients by trial arm
Intervention Control
Clinic-level characteristics:
Number of clinics 11 11
Number of clinics per province
Kunduz 5 5
Nangahar 6 6
Number of health posts (median number per clinic, interquartile range (IQR)) 111 (6, 5–17) 109 (10, 6–13)
Number of patients enrolled (median number per clinic, IQR) 1199 (114, 50–140) 1201 (103, 63–129)
Health post and CHW-level characteristics:
Number of CHWs (median number of CHWs per health clinic, IQR) 120 (8, 6–17) 137 (12, 10–14)
Included in analysis 108 114
CHW gender (n, % male) 75 (62.5) 83 (60.6)
Education level of CHWs, n (%)
None 41 (34.8) 34 (25.0)
Informal education 5 (4.2) 5 (3.7)
Primary 20 (17.0) 20 (14.7)
Secondary 44 (37.3) 42 (30.9)
Post-secondary/higher 8 (6.8) 35 (25.7)
Socioeconomic status of CHWs (n, %)
Below median 59 (51.3) 63 (48.1)
Above median 56 (48.7) 68 (51.9)
Data missing 5 5
Median number of consultations in week prior to the study (IQR) 11 (7–20) 14 (9–19)
Median number of hours in last week performing CHW activities (IQR) 2.5 (1.3–5.7) 5.4 (1.8–9.0)
Patient characteristics:
Number of patients (median per CHW, IQR) 1199 (11.9, 6.7–14) 1201 (7.3, 5.4–16.8)
Number of patients evaluated: 1099 1055
Reasons for exclusion:
Missing treatment or diagnosis data 81 128
Reference diagnosis missing 19 19
Prevalence of malaria in the sample (n, %)
P. vivax 159 (13.2) 194 (16.2)
P. falciparum 45 (3.7) 45 (3.7)
Mixed infection 2 (0.2) 1 (0.1)
Gender of patient (n, % male) 647 (54.6) 674 (56.2)
Age band of patient (n, %)
0–1 year 9 (0.8) 5 (0.4)
1–5 years 82 (6.9) 62 (4.2)
6–10 years 269 (22.8) 171 (14.3)
10–18 years 302 (25.6) 311 (26.0)
> 18 years 520 (44.0) 649 (54.2)
N, % of patients enrolled by male CHW 975 (81.5) 822 (68.6)
N, % of patients enrolled at time of day
Morning (6 am–12 pm) 425 (35.5) 477 (39.8)
Afternoon (12 pm–6 pm) 338 (28.2) 319 (26.6)
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national guidelines, and in a further 10 patients (6%) an-
other antimalarial or combination effective against vivax
was prescribed. Where two lines (Pf and pan) were re-
corded (identifying P. falciparum) 25/38 (66%) were pre-
scribed SP + AS.
Effect of age
A further analysis was undertaken restricted to those
aged 5 years and below or above 5 years, comparing the
primary outcome in each age band. For those under
5 years old, 64/82 (91.4%) in the intervention group and
6/46 (8.7%, p < 0.001) in the control group received ap-
propriate treatment. In those over 5 years old, the rela-
tive proportions were 753/1001 (80.8%, intervention)
and 179/1007 (19.2%, p < 0.001).
Accuracy of mRDTs
Overall sensitivity under these operational conditions
against the PCR result was low and specificity was accept-
able for both pan-specific and falciparum-specific detec-
tion (Table 4). Sensitivity of the pan-specific tests under
operational conditions was very low in the low-endemic
northern province (2.1%, 95% CI: 0.1–11.3) and, although
higher, was less than expected in the highly endemic east-
ern province (62.5%, 95% CI: 45.8–77.3).
To assess the possible causes of low sensitivity of the
tests in detecting P. falciparum, we undertook an ex-
ploratory analysis to test the hypothesis that low parasite
density infections (common in low endemic settings)
may have led to a high rate of false negative mRDT re-
sults when interpreted by CHWs with standard training.
We used the results from the qPCR analysis to approxi-
mate parasite density. The quantitation cycle (Cq) num-
ber for P. falciparum positive patients with mRDT
results (i.e. in the intervention arm) were divided into a
binary variable around the median. Those with a low Cq
number had a higher copy number, indicating a higher
parasite density. Those with Cq lower than the median
(higher concentration of parasite DNA) had 17.4% (4/
23) false negative results vs. those with a higher Cq
(lower concentration of parasite DNA) having 78.3%
(18/23) false negative results (Fisher’s exact test, p <
0.001), suggesting that the low operational sensitivity
when RDTs were interpreted by CHWs was mainly due
to poor test sensitivity at low parasite densities.
Diagnosis, treatment and referral practices
We analysed the actions taken by the CHWs, including
their final diagnosis, treatment and referral practices. In
the intervention mRDT arm, CHWs diagnosed malaria
in 249/1199 patients (20.8%). Of these, 86.6% had a posi-
tive mRDT result (either pan-line, or Pf/pan-line) with
the remainder having a negative test result. In the
mRDT arm, the most common alternative diagnoses to
malaria as recorded by CHWs were either the common
cold (n = 631, 52.6%) or pneumonia (n = 538, 44.9%).
This contrasted with the 1180/1201 (98.3%) diagnosed
with malaria in the control arm and is consistent with
the higher use of co-trimoxazole in the mRDT arm.
There was no difference in the proportion of patients
referred from the village health post to the clinic com-
paring the intervention arm and the control arm (34.6%
vs. 26.4%; p = 0.116), Table 3.
Discussion
This trial in moderate and low endemic areas of
Afghanistan, typical in both epidemiology and healthcare
provision to much of low-resource south Asia, showed
that provision of mRDTs to CHWs together with prac-
tical training on correct use led to a complex picture.
Table 2 Enrolment characteristics of clinics, CHWs and patients by trial arm (Continued)
Evening (6 pm–10 pm) 354 (29.5) 354 (29.5)
Night (11 pm–6 am) 82 (6.8) 50 (4.2)
N, % of patients enrolled by location
Health post 959 (81.4) 803 (68.5)
Patient’s home 207 (17.6) 362 (30.4)
Other 12 (1.0) 25 (2.1)
Reported symptoms (n, %)
Fever 1119 (93.5) 1172 (97.6)
Headache 1113 (92.8) 1119 (93.2)
Vomiting 311 (26.0) 488 (40.7)
Diarrhoea 169 (14.1) 252 (21.0)
Cough 569 (47.5) 416 (34.6)
Other symptom(s) 210 (17.5) 131 (10.9)
Patients with fast breathing (n, %) 57 (4.8) 26 (2.2)
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Fig. 1 Trial profile
Table 3 Primary and secondary outcomes by trial arm
Patient level: n, (%) Intervention n = 1099 Control N = 1055 Risk ratio (95% CI) p value
Primary outcome
Appropriate treatment of malaria by CHWsa 828 (75.3) 185 (17.5) 3.72 (2.40–5.77) <0.001
Secondary outcomes
Malaria negative patients prescribed antimalarial drug (n = 1875) 95 (10.0) 813 (87.6) 0.11 (0.08–0.15) <0.001
P. falciparum malaria cases prescribed an ACT (n = 86) 12 (28.6) –b –
P. vivax malaria cases prescribed CQ (n = 346) 70 (45.1) 164 (85.9) 0.43 (0.31–0.59) <0.001
Malaria negative patients prescribed co-trimoxazole (n = 1756) 613 (67.2) 295 (35.0) 1.98 (1.18–3.33) 0.012
Referral practices:
Referral on to formal health services (n = 2399) 414 (34.6) 317 (26.4) 1.53 (0.89–2.63) 0.116
aComposite measure defined against the malaria PCR result for each patient: falciparum or mixed-species malaria treated with SP/AS; vivax malaria treated with
CQ (regardless of accompaniment with SP); and PCR-confirmed negative cases receiving no antimalarial drug
bACTs were not used in the control arm, as they can only be prescribed based on parasitological diagnosis. In the intervention arm, N = 42
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Targeting of antimalarials (the primary outcome) im-
proved significantly, mediated by much lower rates of pre-
scribing antimalarials to patients without malaria
parasites. This useful outcome was offset by a significant
reduction in prescribing antimalarials to those who did
have malaria, both vivax and falciparum. ACTs were given
to only a quarter of cases of falciparum malaria in the
intervention arm. Antibiotic prescribing increased in the
intervention arm, possibly indicating a switch from over-
prescribing antimalarials to overprescribing antibiotics.
In comparison to PCR, the operational sensitivity of
WHO-approved mRDTs when used by CHWs was poor,
possibly because of infections with low parasite density,
which are common in low-transmission settings. Limited
laboratory testing has suggested that, in common with
many other tests, whilst the mRDTs used in this study
have good sensitivity for vivax malaria at high parasitae-
mias, it may decrease rapidly (to around 50% at low
parasitaemias) [18]. However, the prescribing practices
of CHWs were highly concordant with RDT result, sug-
gesting that if tests appropriate to the local setting were
available, there would be a substantial positive effect on
prescribing of antimalarials. In African settings CHWs
have proved willing to adapt practice to RDTs [19, 20].
CHWs start with a history of fever in considering mal-
aria; in the absence of either clear alternative diagnoses,
or a test, malaria is unlikely but almost impossible to
exclude.
WHO currently recommends diagnostic testing with
WHO-approved RDTs prior to prescribing antimalarials.
Trials in Africa including those in the formal secondary
setting [21], district health posts (similar to this setting)
[22] and private sector providers [23] support this ap-
proach, although health worker adherence to test results
is variable [6, 24]. Translating this to the much lower in-
cidence settings where most malaria is vivax and parasite
density will be lower should be undertaken with caution
in the absence of relevant data. This trial supports the
principle that CHWs will change prescribing behaviour
and improve targeting in acute febrile illness with
mRDTs and training, but raises significant practical con-
cerns. In particular, without mRDTs with greater oper-
ational sensitivity in this epidemiological setting, the
risks of missing true cases of malaria, including falcip-
arum, are non-trivial. In Africa the risks of missing fal-
ciparum malaria are emphasised early in training, and
studies show it is very rare for test positive cases not to
be prescribed antimalarials [13]. In south Asia the true
risk of malaria is lower, and it is possible that this drives
behaviour [25].
The introduction of mRDTs, whilst reducing the over-
use of antimalarial drugs, had the effect of increasing the
use of antibiotics (co-trimoxazole) in malaria negative
cases; this finding is similar to operational studies in
Africa [5, 22], and recent studies suggest that this is a
widespread concern in the context of rising antibiotic re-
sistance as a consequence of overuse [26]. A previous in-
dividually randomised trial at a higher level of the health
system suggested that the better trained personnel in
those centres are more likely to diagnose malaria with
mRDTs [11], but also tend to switch from overuse of an-
timalarials to higher use of antibiotics. Interventions are
Fig. 2 Effect of malaria RDTs on accuracy of malaria treatment at
health post level
Table 4 Sensitivity and specificity of mRDTs used in low and high transmission areas judged against PCR
Sensitivity n/N (%, 95% CI) Specificity n/N (%, 95% CI)
Pan-specifica
Overall 122/225 (54.2, 47.5–60.9) 891/974 (91.5, 89.5–93.2)
Low transmission 1/47 (2.1, 0.1–11.3) 418/419 (99.8, 98.7–100)
High transmission 121/178 (68.0, 60.6–74.8) 473/555 (85.2, 82.0–88.1)
Pf-specific
Overall 25/47 (53.2, 38.1–67.9) 1097/1133 (96.8, 95.6–97.8)
Low transmission 0/7 –
High transmission 25/40 (62.5, 45.8–77.3) 645/681 (94.7, 92.8–96.3)
aDetects any Plasmodium species including P. vivax and P. falciparum
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required which improve prescribing practices in patients
with non-severe fever.
The study was designed to assess the effectiveness of
the mRDT intervention under field operational condi-
tions within a widely accessed part of the health service
in malaria endemic areas of Afghanistan, and has the ad-
vantages and limitations of operational studies. The clus-
ter design allowed a robust measurement of the effect of
mRDTs on prescription of antimalarial drugs by CHWs
and is accepted as a more reliable approach than indi-
vidual patient randomised trials conducted in clinics, be-
cause clinicians influence one another. Training
followed the approved national guidelines for the use of
mRDTs, which closely match the WHO standard guide-
lines for training and use of mRDTs, and so is generalis-
able. The clinics chosen were representative of most of
Afghanistan’s health service, and were similar to many
CHW systems in low-resource south Asia. The main
findings and conclusions should therefore be applicable
to other countries in the region. The main limitations
were imposed by having to work through relatively un-
skilled CHWs in a relatively unstable area. In particular
it was not realistic to get blood slides made to supple-
ment PCR data and/or to follow patients up into the
community. PCR is significantly more sensitive than mi-
croscopy, but in a low-transmission setting it is unlikely
that a PCR positive malaria case would not be clinically
relevant [27]. If microscopy could have been reliably
used as a gold standard in this clinical setting, then sen-
sitivity of the test may have been reportedly higher.
Lastly, a cost-effectiveness analysis was not part of this
study, but it is an important consideration for policy de-
cisions driving the placement of mRDTs at the facility
and/or community level [28].
Use of mRDTs by CHWs has a potential advantage of
improving surveillance of disease based on parasito-
logical diagnosis. This is particularly relevant to malaria
epidemiology in Afghanistan, which is heterogeneous. In
the north of the country there is very little transmission,
and elimination is being actively pursued. This requires
an ability to detect and respond to outbreaks with pre-
ventative interventions such as insecticide-treated nets.
However, the performance of the mRDTs at the commu-
nity level may reduce the attractiveness of this tool in
favour of more sensitive tests. In the east of the country
, the malaria programme is still in the control phase,
where mRDTs could provide improved surveillance and
targeting of preventative measures.
The increase in antibiotic use in the intervention arm
is potentially a concern. The World Health Assembly
and UN General Assembly have recently highlighted the
serious risk that is posed by antibiotic resistance. Over-
use of antibiotics in south Asia is driving substantial
antibiotic resistance [29]. If one of the effects of mRDTs
is to lead to a switch from overprescribing of antimalar-
ial drugs to overprescription of antibiotics, this would be
a concerning unintended consequence.
Conclusions
In low prevalence areas such as Afghanistan, mRDTs for
malaria have at least three potential roles: to identify the
relatively uncommon cases of true malaria, especially fal-
ciparum malaria; to provide epidemiological surveillance
data in areas considering elimination; and to reassure
prescribers that not prescribing an antimalarial is rea-
sonable. The main advantage of mRDTs at the commu-
nity level is to reduce the overuse of antimalarial drugs
in malaria negative patients. However, currently available
mRDTs may miss a substantial proportion of cases of
malaria. Although using mRDTs led to reductions in the
number of inappropriate doses of antimalarials, mRDTs
may also lead to overprescription of antibiotics. Any po-
tential role for improving surveillance should consider
the operational sensitivity of mRDTs, which may be too
low for detecting some malaria infections; higher sensi-
tivity tests may be useful in these settings. The risks
identified in this study need to be balanced against the
advantages of rolling out mRDTs amongst CHWs.
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